Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on February 25, 2016, reporting events occurring on February 23 and 24, 2016. The filing focuses on the presentation of long-term clinical data for the Argus II Retinal Prosthesis System, a medical device designed to restore visual function to patients blinded by Retinitis Pigmentosa (RP).
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a Current Report regarding a specific corporate event rather than a periodic financial statement.
Material Changes and Clinical Data
- Clinical Presentation: On February 24, 2016, Dr. James T. Handa presented five-year post-implant study data for the Argus II at the 39th Annual Macula Society Meeting in Miami Beach, Florida.
- Study Scope: The data covers an ongoing clinical trial (NCT00407602) involving 30 individuals from 10 clinical centers who were blinded by RP or similar disorders.
- Key Findings: The study represents over 200 cumulative patient-years of follow-up. Results demonstrate the safety, reliability, and ability of the prosthesis to improve visual function over an extended duration.
Outlook, Risks, and Management Commentary
Management highlighted the successful long-term performance of the Argus II system as a key milestone. The filing includes a press release and the slide presentation from the Macula Society Meeting as exhibits. No specific forward-looking financial guidance, new risk factors, or unusual items were disclosed in this text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.2) for additional details on the clinical outcomes.
- Review the slide presentation (Exhibit 99.1) for granular data on safety and performance metrics.
- Confirm the regulatory status of the Argus II system in relevant markets following this five-year data release.
- Check subsequent filings for any impact of this clinical data on the company's commercial strategy or partnership discussions.